Antheia secures $80 million conditional loan from DOD to expand U.S. generic drug manufacturing

Antheia, a biosynthesis manufacturer, has been awarded a conditional loan of $80 million from the U.S. Department of Defense.

The funding is aimed at onshoring the company’s generic drug production, boosting domestic manufacturing capacity.

Antheia says the loan will enable it to broaden its pipeline and lessen reliance on overseas sources, supporting national security and supply‑chain goals.